Investors Ignore Trump On Pricing
When Donald Trump said on Jan. 11 that the drug companies were “getting away with murder” on pricing, some took his words seriously. But his shapeless message had no meaning for the markets. Investors glanced up from their screens momentarily but they don’t believe he will do anything about drug pricing.
You may also be interested in...
Drug makers are embracing different strategies on the pricing issue as the industry marches closer to a confrontation with President-Elect Trump over the cost of medicines.
Pharmaceutical manufacturers have been waiting for Trump’s ax to fall – and it finally did, on the final full day of the industry’s biggest business meeting of the year.
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.